GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Equity-to-Asset

Celyad Oncology (XBRU:CYAD) Equity-to-Asset : 0.08 (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Celyad Oncology's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €1.02 Mil. Celyad Oncology's Total Assets for the quarter that ended in Jun. 2023 was €12.18 Mil.

The historical rank and industry rank for Celyad Oncology's Equity-to-Asset or its related term are showing as below:

XBRU:CYAD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.08   Med: 0.53   Max: 0.7
Current: 0.08

During the past 12 years, the highest Equity to Asset Ratio of Celyad Oncology was 0.70. The lowest was 0.08. And the median was 0.53.

XBRU:CYAD's Equity-to-Asset is ranked worse than
83.14% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs XBRU:CYAD: 0.08

Celyad Oncology Equity-to-Asset Historical Data

The historical data trend for Celyad Oncology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Equity-to-Asset Chart

Celyad Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.51 0.47 0.55 0.22

Celyad Oncology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.53 0.49 0.22 0.08

Competitive Comparison of Celyad Oncology's Equity-to-Asset

For the Biotechnology subindustry, Celyad Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celyad Oncology's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Equity-to-Asset falls into.



Celyad Oncology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Celyad Oncology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=4.317/19.716
=

Celyad Oncology's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )=Total Stockholders Equity/Total Assets
=1.019/12.178
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celyad Oncology  (XBRU:CYAD) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Celyad Oncology Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Celyad Oncology (XBRU:CYAD) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines